Ares set to make offer for whole of Stallergenes

Ares Life Sciences, a Switzerland-based healthcare investment firm, must launch a takeover bid for Stallergenes, after acquiring 45.86% of the French allergy-specialist from Wendel, a French investment firm, for €59 per share. Wendel will receive around €358.8 million from Ares and is expected to declare a capital gain of around €300 million. Ares has told Stallergenes that it does not foresee any change within Stallergenes' jobs, salary or human resources policies.

Under French law, Ares must file a tender offer for all the remaining outstanding shares of Stallergenes - held either...